Sort
48,018 grants matching “immunotherapy”
Correlative biomarkers of IL-6 blockade combined with checkpoint inhibition
$563,722Janice M. Mehnert · New York University School Of Medicine · R01 · FY2024 · CA
Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy
$563,656Christiane Querfeld · Beckman Research Institute/City Of Hope · R01 · FY2022 · CA
Cutaneous T cell lymphoma: a paradigm for dissecting susceptibility and resistance to checkpoint inhibition therapy
$563,656Christiane Querfeld · Beckman Research Institute/City Of Hope · R01 · FY2021 · CA
Defining the β-catenin/CBP-catenin/CBP axis in head and neck cancer
$563,548Maria A Kukuruzinska · Boston University Medical Campus · R01 · FY2021 · DE
Investigation of the role of epithelial-mesenchymal plasticity in renal cell carcinoma
$563,322Giannicola Genovese · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
Multivalent Small Circular mRNA Vaccines for Melanoma Combination Immunotherapy
$563,293Guizhi Zhu · University Of Michigan At Ann Arbor · R01 · FY2025 · CA
Targeting S1P-ACC Axis to Overcome MDSC Suppression
$563,233Shikhar Mehrotra · Medical University Of South Carolina · R01 · FY2025 · CA
Memory, Phenotype, and Function of TB-reactive Human MR1 Restricted T cells
$563,233David M. Lewinsohn · Oregon Health & Science University · R01 · FY2022 · AI
Dissecting the immunomodulatory effects of NK cells on immune responses to cancer
$563,228Kevin C Barry · Fred Hutchinson Cancer Center · R01 · FY2025 · CA
Actionable categories of avoidable hospital care among adults with cancer
$563,198Arthur Seokjae Hong · Ut Southwestern Medical Center · R01 · FY2025 · CA
SYNTHESIS OF CARBOHYDRATE IMMUNOSTIMULANTS
$563,190Derek S Tan · Sloan-Kettering Inst Can Research · R01 · FY2012 · GM
SYNTHESIS OF CARBOHYDRATE IMMUNOSTIMULANTS
$563,190Derek S Tan · Sloan-Kettering Inst Can Research · R01 · FY2011 · GM
Expanding the cancer paralog genetic interaction map to enable precision oncology
$563,170Alice Berger · Fred Hutchinson Cancer Center · R01 · FY2024 · CA
Pathogenesis and Chemotherapy of Herpesvirus Infection
$563,106Jeffrey Cohen · National Institute Of Allergy And Infectious Diseases · ZIA · FY2021 · AI
Sulindac sensitizes colorectal cancer to anti-PD-L1 therapy
$563,009Yaguang Xi · University Of Georgia · R01 · FY2023 · CA
Transformative personalized vascular disrupting cancer immunotherapy
$562,946George Coukos · University Of Pennsylvania · R01 · FY2014 · CA
PET Imaging of Glutamine Metabolism and Glutamate Transport to Guide Metabolically Targeted Therapy in Triple-Negative Breast Cancer
$562,902David A Mankoff · University Of Pennsylvania · R01 · FY2022 · CA
Dual p300 and p53 reactivation in HPV+ head and neck cancer
$562,898Quintin Pan · Case Western Reserve University · R01 · FY2025 · DE
Project 3: Tools for Capturing Immune Cell/Cancer Cell Interactions in Cancer Immunotherapies and Combination Immunotherapies
$562,890James R. Heath · Institute For Systems Biology · U54 · FY2017 · CA
Spatially resolved, single cell biomarkers of B cell lymphoma
$562,886Akil Merchant · Cedars-Sinai Medical Center · R01 · FY2023 · CA
IL-1 HOMOLOGUES PROMOTE THE ACUTE INFLAMMATORY RESPONSE TO MELANOMA
$562,884Michael T Lotze · University Of Pittsburgh At Pittsburgh · P01 · FY2007 · CA
Integrated Discovery Pipeline for Tumor Neoantigens
$562,825Beatriz M. Carreno · University Of Pennsylvania · R01 · FY2016 · CA
BD FACSDiscover S8 Spectral and Imaging Cell Sorter
$562,818Christine Beeton · Baylor College Of Medicine · S10 · FY2025 · OD
Phase 1 Evaluation of Enhanced Natural Killer Cells as a Treatment Strategy in Non-Small cell Lung Cancer Patients Refractory to PD-1/PD-L1 Immune Checkpoint Inhibitors
$562,792Miguel Angel Villalona · University Of California-Irvine · R01 · FY2025 · CA
Defining mechanisms to promote antitumor immunity by modulating one-carbon metabolism
$562,761Arlene H Sharpe · Harvard Medical School · R01 · FY2025 · CA